News & Updates

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

In individuals with advanced urothelial carcinoma (UC), a first-line maintenance treatment regimen comprising a combination of avelumab and best supportive care (BSC) provided better survival benefit than BSC alone, according to long-term and subgroup analyses of the phase III JAVELIN Bladder 100 trial presented at ASCO GU 2022.